{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T22:32:25Z","timestamp":1774305145313,"version":"3.50.1"},"reference-count":26,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Severe asthma, which is characterized by persistent symptoms despite standard therapies, presents a significant clinical challenge. Biologic therapies targeting specific inflammatory pathways offer a potential avenue for achieving disease remission. This retrospective study evaluates the effectiveness of biologic therapies in achieving remission in severe asthma within a central Romanian cohort. Methods: Forty-eight patients with severe asthma treated with omalizumab, benralizumab, or dupilumab (2020\u20132025) were assessed. Clinical remission was defined using ACT scores, exacerbation frequency, corticosteroid use, and FEV1. Biological remission was determined using FeNO and eosinophil levels. Statistical analysis was performed to compare treatment outcomes. Results: At 12 months, 75% of patients achieved biological remission, and 75% reached clinical remission criteria. Significant improvements were observed in FEV1 (p &lt; 0.001), eosinophil counts (p &lt; 0.001), and ACT scores (p &lt; 0.001). Complete remission, encompassing clinical, biological, and functional normalization, was observed in 54.2% of patients. Conclusion: Biologic therapies demonstrate promise in inducing comprehensive remission in severe asthma, supporting their role in improving disease control and lung function. Further research with larger cohorts is warranted.<\/jats:p>","DOI":"10.3390\/life15071113","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T10:46:05Z","timestamp":1752662765000},"page":"1113","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Is Biologic Therapy an Effective Tool for Achieving Remission in Severe Asthma? A Retrospective Study in Central Romania"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9439-0590","authenticated-orcid":false,"given":"Corina","family":"M\u0103rginean","sequence":"first","affiliation":[{"name":"Oncology and Palliative Care Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0882-870X","authenticated-orcid":false,"given":"Drago\u0219","family":"Hu\u021banu","sequence":"additional","affiliation":[{"name":"Pulmonology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1695-6990","authenticated-orcid":false,"given":"Mara Andreea","family":"Vultur","sequence":"additional","affiliation":[{"name":"Pulmonology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9di-Katalin","family":"S\u00e1rk\u00f6zi","sequence":"additional","affiliation":[{"name":"Pulmonology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3558-2856","authenticated-orcid":false,"given":"Edith-Simona","family":"Iano\u0219i","sequence":"additional","affiliation":[{"name":"Pulmonology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Beatrice","family":"Iano\u0219i","sequence":"additional","affiliation":[{"name":"Pulmonology Clinic, Mure\u0219 County Clinical Hospital, T\u00e2rgu Mure\u0219, 540011 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Safta","sequence":"additional","affiliation":[{"name":"Pulmonology Clinic, Mure\u0219 County Clinical Hospital, T\u00e2rgu Mure\u0219, 540011 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1990-6767","authenticated-orcid":false,"given":"Gabriela","family":"Jimborean","sequence":"additional","affiliation":[{"name":"Pulmonology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-0121","authenticated-orcid":false,"given":"Corina Eugenia","family":"Budin","sequence":"additional","affiliation":[{"name":"Pathophysiology Department, George Emil Palade University of Medicine, Pharmacy, Science and Technology of T\u00e2rgu Mure\u0219, 540139 T\u00e2rgu Mure\u0219, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"key":"ref_1","unstructured":"(2025, March 15). Global Initiative for Asthma\u2014GINA. 2024 GINA Main Report. Available online: https:\/\/ginasthma.org\/2024-report\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying anti-asthmatic drugs","volume":"399","author":"Lommatzsch","year":"2022","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma Remission: What Is It and How Can It Be Achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S2213-2600(24)00304-7","article-title":"Asthma remission: A call for a globally standardised definition","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(23)00415-0","article-title":"Pioneering a paradigm shift in asthma management: Remission as a treatment goal","volume":"12","author":"Lommatzsch","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jaip.2024.01.023","article-title":"Phenotyping of Severe Asthma in the Era of Broad-Acting Anti-Asthma Biologics","volume":"12","author":"Bourdin","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e12047","DOI":"10.1002\/clt2.12047","article-title":"Role of IL-17 in atopy\u2014A systematic review","volume":"11","author":"Hofmann","year":"2021","journal-title":"Clin. Transl. Allergy"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2003393","DOI":"10.1183\/13993003.03393-2020","article-title":"Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation","volume":"58","author":"Busse","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_10","unstructured":"Sinyor, B., and Perez, L.C. (2021, November 07). Pathophysiology of Asthma, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551579\/."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2000260","DOI":"10.1183\/13993003.00260-2020","article-title":"Anti-alarmins in asthma: Targeting the airway epithelium with next-generation biologics","volume":"56","author":"Porsbjerg","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_12","unstructured":"(2025, June 29). ORDIN 1301 11\/07\/2008\u2014Portal Legislativ. Available online: https:\/\/legislatie.just.ro\/Public\/DetaliiDocument\/95626."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): A randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_15","unstructured":"(2025, March 17). Thieme E-Journals\u2014Seminars in Respiratory and Critical Care Medicine\/Abstract. Available online: https:\/\/www.thieme-connect.com\/products\/ejournals\/abstract\/10.1055\/s-0042-1743290."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Demenciuc, N., Budin, C.E., Ureche, C., Stoian, M., Nicola-Varo, T., Baba, D.F., P\u0103tr\u00eenta\u0219u, D.E., and Deleanu, D. (2025). Differential Analysis of Hemogram Parameters and Cellular Ratios in Severe Asthma Exacerbations: A Comparative Study of Eosinophilic and Non-Eosinophilic Phenotypes. Life, 15.","DOI":"10.3390\/life15060970"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaip.2021.12.027","article-title":"Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma","volume":"10","author":"Porsbjerg","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring Definitions and Predictors of Severe Asthma Clinical Remission after Biologic Treatment in Adults","volume":"210","author":"Scelo","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/all.15867","article-title":"Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients","volume":"79","author":"Thomas","year":"2024","journal-title":"Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1111\/all.15693","article-title":"Factors associated with suboptimal response to monoclonal antibodies in severe asthma","volume":"78","author":"Urrutia","year":"2023","journal-title":"Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/MCP.0000000000001067","article-title":"Long-term safety, durability of response, cessation and switching of biologics","volume":"30","author":"Mohan","year":"2024","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/resp.14520","article-title":"Biologics for severe asthma-Which, when and why?","volume":"28","author":"Shah","year":"2023","journal-title":"Respirology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/all.14425","article-title":"EAACI Biologicals Guidelines-Recommendations for severe asthma","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic Therapies for Severe Asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1113\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:10:32Z","timestamp":1760033432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["life15071113"],"URL":"https:\/\/doi.org\/10.3390\/life15071113","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]}}}